Navigation Links
Genetic predictor of breast cancer response to chemotherapy
Date:5/11/2012

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy.

The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most benefit to patients whose cancer is driven by HER2 and antiestrogens benefit patients whose breast cancer is hormonally driven. Gene signatures are increasingly available for different cancer types and can be used to predict patient prognosis.

Researchers from McMaster University, in association with the Juravinski Hospital and Cancer Center, analyzed the expression of the enzyme TOP2A (DNA topoisomerase) and β-tubulin, which are the targets of commonly used chemotherapy drugs (anthracycline and taxane) in hundreds of breast tumors. Combining the results from the tumor samples analyses allowed the researchers to build gene expression 'signatures' that measure the susceptibility of tumor cells to chemotherapy.

Both of the 'signatures' were separately able to predict which patients achieved a complete response (where invasive or metastatic cancer could no longer be detected) and together the two indices together were even more accurate at predicting response to chemotherapy.

Prof John Hassell, who led this study, commented, " Our results clearly demonstrate the practicality of using gene expression to personalize chemotherapy treatment for breast cancer patients. Identifying patients who will not benefit from a specific treatment means that they can be moved to a different treatment plan, and the earlier appropriate treatment is started the more likely it is that the patients will benefit from it."


'/>"/>
Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. Advanced genetic screening method may speed vaccine development
2. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
3. Some women may be genetically predisposed to smoking-related hot flashes
4. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Research Gets Closer to Genetic Roots of Glaucoma
7. Genetic variants, tobacco exposure and lung cancer risk
8. Study of half siblings provides genetic clues to autism
9. Certain Genetic Regions May Be Tied to Osteoporosis
10. Head, Body Lice Are Genetically Very Similar
11. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PhD Box ... the onset of the research process by offering assistance for ... to the repertoire of services that the company provides for ... behind launching a dedicated proposal writing service is that this ... new to the research process find it difficult to draft ...
(Date:5/23/2013)... Kitchen on Fire announces ... most advanced culinary technique series currently offered at this ... knowledge of how to purchase, butcher and cook the ... of organic, local ingredients. The new Intermediate Series consists ... each. The next series begins on Sunday, June 2, ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... recently and they are now actively providing expert opinion ... Side Effects lawsuits. , According to court documents, ... in Illinois Southern District Court (case no. 3:2013cv50102) alleging ... Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, is mainly used ...
(Date:5/22/2013)... 2013 MileageAds.com, an American based full ... companies in the Stocks and Bonds Sector to display ... advertise with MileageAds will have the opportunity to take ... Stocks and bonds companies who accept Mileageads.com’s invitation will ... a specific, targeted audience on the internet ...
(Date:5/22/2013)... On May 16, 2012, LifeHealthPro reported that, ... concierge can help families negotiate lower costs for all aspects ... announces their top 3 reasons to hire a funeral ... U.S. having dropped 7.3 percent from $55,438 to $51,404 since ... 12.6% of an average U.S. households annual income. , Funeral ...
Breaking Medicine News(10 mins):Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 3Health News:New Lawsuit on Pradaxa Brain Hemorrhage: Now, AttorneyOne Can Provide Advice 2Health News:Mileageads.com Ad Network Now Invites Companies in Stocks and Bonds Services Sector to Advertise on Their Ad Network 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Certain types ... smokers who are generally anxious, according to a new study. ... to tune out anti-smoking videos that warn how smoking can ... harm others. "If you look at health messages, there ...
... Experts from The Neuroscience Institute at NYU Langone Medical ... discussions at the Society for Neuroscience 41st Annual Meeting ... meeting presents an opportunity for leading scientists from around ... for treating diseases and conditions of the brain," said ...
... Researchers at the University of Liverpool and the universities ... that cases of severe pneumonia among young children are ... cooking stoves. The research, published in the ... smoke from open fires and dirty cooking stoves, the ...
... scientists have developed a new technique using stem cells, ... disease. The technique could be developed for application in ... Thompson lead the research from the Florey Neuroscience Institutes ... the newly established Stem Cells Australia collaboration being launched ...
... THURSDAY, Nov. 10 (HealthDay News) -- Despite the known dangers ... but almost 70 percent want to quit, a new government ... Tim McAfee, director of the Office on Smoking and Health ... during a noon press conference Thursday. There was a ...
... (HealthDay News) -- Eating a high-fiber diet may reduce your ... cereal and whole grains, according to a new review. ... a total of nearly 2 million people. Compared with the ... increase in intake of total dietary fiber and cereal fiber ...
Cached Medicine News:Health News:Negative Anti-Smoking Ads Turn Off Anxious Viewers 2Health News:Woodsmoke from cooking fires linked to pneumonia 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3Health News:Most Smokers Want to Quit, CDC Report Finds 2Health News:Most Smokers Want to Quit, CDC Report Finds 3Health News:Most Smokers Want to Quit, CDC Report Finds 4Health News:High-Fiber Diet May Help Thwart Colon Cancer 2
(Date:5/22/2013)... Z-Medica, a leading developer and marketer of ... line of products designed to meet the unique needs ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ... all custom-designed to help responders stop bleeding fast and ... a hospital or trauma center. The line includes products ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
(Date:5/22/2013)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the following conferences. , Deutsche Bank 38th ... 29, 2013 , Presentation time: 12:00 p.m. P.T. ... Presentation date: Wednesday June 5, 2013 , Presentation time: ... live webcast and 30-day archive of these presentations will be ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... ~ Valopicitabine achieved both primary and secondary ... observed between,valopicitabine and ribavirin ~, CAMBRIDGE, Mass., ... today announced results from a phase II ... of,valopicitabine (NM283), Idenix's lead drug candidate for ...
... Demonstrates Significant,Additional Improvement for Patients on Pagoclone, ... Pharmaceuticals, Inc. today announced that results from ... in persistent,developmental stuttering will be presented today ... Clinical Drug Evaluation Unit (NCDEU), sponsored,by National ...
Cached Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: